Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BOTOX for Forehead and Glabellar Rhytides
NCT02261467Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in forehead rhytides and glabellar rhytides comparing OnabotulinumtoxinA with Placebo -> OnabotulinumtoxinA (2 arms). Primary endpoint: Facial Wrinkle Scale Ratings of Forehead Line Severity at Maximum Eyebrow Elevation at Day 30. Started Oct 2014; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
forehead rhytidesglabellar rhytides
Beyond the preview
Go deeper on NCT02261467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261467.